Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 5:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Amoxicillin-Potassium Clavulanate Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions

NCT00778661
View directory record Official record
Conditions
Healthy
Interventions
amoxicillin 400mg + clovalunic acid 57.5mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

NCT03358576
View directory record Official record
Conditions
Intra Abdominal Infections
Interventions
Ertapenem, Sulopenem-Etzadroxil/Probenecid, Ciprofloxacin, Metronidazole, Amoxicillin-Clavulanate, Sulopenem
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Chula Vista, California • Torrance, California • Idaho Falls, Idaho + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 23 Months
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 29, 2026, 5:23 PM EDT
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections

NCT01110382
View directory record Official record
Conditions
Abscess, Intra-Abdominal, Abdominal Abscess, Abdomen, Acute, Abdominal Pain, Appendicitis, Rupture, Infection, Intestinal Perforation, Peritonitis, Ileus
Interventions
Doripenem, Meropenem placebo, Meropenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
San Diego, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fed Conditions

NCT00778284
View directory record Official record
Conditions
Healthy
Interventions
Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 22, 2008 · Synced Sep 29, 2026, 5:23 PM EDT
Not listed Phase 4 Interventional

Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair

NCT04573504
View directory record Official record
Conditions
Vaginal Laceration During Delivery
Interventions
Augmentin/Flagyl or Augmentin/Clindamycin, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media

NCT02630992
View directory record Official record
Conditions
Acute Otitis Media
Interventions
Amoxicillin-Clavulanate potassium
Drug
Lead sponsor
Nader Shaikh
Other
Eligibility
6 Months to 23 Months
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 1 Interventional

Phase I Study of Safety and Immunogenicity of ADU-623

NCT01967758
View directory record Official record
Conditions
Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions
Cohort 1, Cohort 2, Cohort 3, Antibiotics
Biological · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea

NCT04414722
View directory record Official record
Conditions
Antibiotic-associated Diarrhea
Interventions
Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet, BB-12, Control Yogurt
Drug · Biological · Other
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Sep 29, 2026, 5:23 PM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 3 Interventional

Comparative Study of the Safety and Efficacy of Clarithromycin Extended-Release Tablets Versus Amoxicillin-Clavulanate for the Treatment of Acute Bacterial Sinusitis

NCT00644553
View directory record Official record
Conditions
Acute Bacterial Sinusitis (ABS)
Interventions
Clarithromycin, Amoxicillin
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Birmingham, Alabama • Phoenix, Arizona • Clovis, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2008 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Not applicable Interventional Results available

Comparing Healthcare Utilization Between Adenotonsillectomy Patients With and Without Postoperative Antibiotic Use

NCT01561703
View directory record Official record
Conditions
Snoring, Strep Throat
Interventions
Antibiotic
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Up to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 2Phase 3 Interventional

The Use of Prophylactic Antibiotics In the Management of Dog Bites

NCT00185939
View directory record Official record
Conditions
Bite, Wound, Infection
Interventions
Augmentin
Drug
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Burlingame, California • San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2006 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis

NCT01825408
View directory record Official record
Conditions
Sinusitis
Interventions
Doxycycline, Azithromycin, Augmentin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 3, 2017 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 4 Interventional

Comparison Study Between Cefdinir & Amoxicilline/Clavulanate in Acute Sinusitis and Assessment of Quality of Life

NCT00147914
View directory record Official record
Conditions
Acute Bacterial Sinusitis
Interventions
Cefdinir (drug), amoxicillin/clavulanate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Sep 29, 2026, 5:23 PM EDT
Recruiting Phase 4 Interventional

Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis

NCT06076304
View directory record Official record
Conditions
Sinus Infection, Acute Sinusitis
Interventions
amoxicillin/clavulanate potassium, Placebo, Budesonide nasal spray
Drug
Lead sponsor
Daniel Merenstein
Other
Eligibility
18 Years to 75 Years
Enrollment
3,720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
7
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 29, 2026, 5:23 PM EDT
Terminated Phase 2 Interventional Results available

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

NCT05753735
View directory record Official record
Conditions
Pancreatic Fistula
Interventions
Piperacillin/Tazobactam, Amoxicillin/ Clavulanic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 3 Interventional Results available

Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults

NCT03357614
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Sulopenem, Sulopenem-Etzadroxil/Probenecid, Ertapenem, Ciprofloxacin, Amoxicillin-clavulanate
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Enrollment
1,395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
15
States / cities
Bellflower, California • Chula Vista, California • La Mesa, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2020 · Synced Sep 29, 2026, 5:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

NCT02605122
View directory record Official record
Conditions
Community-acquired Bacterial Pneumonia
Interventions
Solithromycin, Standard of Care
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
2 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2019 · Synced Sep 29, 2026, 5:23 PM EDT
Completed Phase 4 Interventional Results available

Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial

NCT01919411
View directory record Official record
Conditions
Sinusitis
Interventions
Amoxicillin-Potassium Clavulanate, Placebo
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 29, 2026, 5:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination

NCT06733675
View directory record Official record
Conditions
Healthy Volunteer, Pharmacokinetics, Safety, Drug-Drug Interaction (DDI), FDC
Interventions
Ledaborbactam etzadroxil, Ceftibuten, Ceftibuten-ledaborbactam etzadroxil, Esomeprazole, amoxicillin-clavulanate
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 29, 2026, 5:23 PM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 29, 2026, 5:23 PM EDT
Not listed Phase 4 Interventional

Efficacy of Oral vs IV Antibiotics in the Treatment of Orofacial Osteomyelitis

NCT05867654
View directory record Official record
Conditions
Osteomyelitis of Jaw
Interventions
Amoxicillin-clavulanate 875mg/125mg q12hrs, oral clindamycin 300mg q6hrs, Levofloxacin 750mg QID
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 29, 2026, 5:23 PM EDT